Clinical trial
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal…
NCT00394433 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00394433 |
|---|---|
| Title | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer |
| Official title | A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Stomach Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Docetaxel, Cisplatin, Irinotecan |
| Enrollment | 38 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Oct 1, 2016 |
| First posted | Nov 1, 2006 |
| Last update posted | Aug 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: